Blood and Marrow Transplantation Reviews: Optimal Use of Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin’s Lymphoma

The goal of this educational program is to improve the treatment of patients with multiple myeloma (MM) and non-hodgkin lymphoma (NHL) through the dissemination of information about stem cell transplantation and mobilization for autologous hematopoietic cell transplantation. The data for stem cell transplantation in MM is rapidly changing. The techniques of mobilization are still evolving.

Blood and Marrow Transplantation Reviews: Breakthrough Therapies for Acute Graft-Versus-Host-Disease

Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.

Blood and Marrow Transplantation Reviews: Optimal Use of Stem Cell Mobilization in Patients with Hematologic Malignancies

Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.

Blood and Marrow Transplantation Reviews: Examining Targeted Therapies for Hodgkin Lymphoma in the Post-Transplant Setting: Reason for Optimism

Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.

Blood and Marrow Transplantation Reviews: Management of Multiple Myeloma: Using Emerging Therapies with ASCT

In this CME activity, leading experts in multiple myeloma will review changes in the treatment paradigm, optimal patient selection for transplant, and data from recent clinical trials. They will also provide insight into new strategies for individualized management, the role of early versus late transplant, and how to incorporate novel therapies into clinical practice.